ArticleJournal of hematology & oncology2022
hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype.
Article in Journal of hematology & oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- Overconsumption of fructose aggravates acute GVHD by inducing gut dysbiosis and promoting macrophage-mediated inflammatory response.Gut microbes · 2026Article
- Patients with steroid-refractory gastrointestinal aGVHD respond to ROCK2 inhibitor rapidly.Annals of hematology · 2026Article
- The roles and clinical applications of mesenchymal stem cells and their exosomes in hematologic diseases.Stem cell research & therapy · 2025Review
- Extracellular vesicles for macrophage reprogramming: an emerging paradigm in immunomodulatory therapeutics.Journal of biological engineering · 2025Review
- Immunological mechanisms underlying the novel application of mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) in graft-versus-host disease (GvHD) therapy.Molecular biology reports · 2025Review
- Nanographene Oxide Attenuates Acute GVHD by Modulating Macrophage Polarization in a Xenogeneic Mouse Model.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Donor macrophage pyroptosis contributes to the development of aGVHD.Science China. Life sciences · 2025Article
- The rise of exosome-mediated mechanisms in MSC therapy.Journal of translational medicine · 2025Article
- Research landscape and trends of human umbilical cord mesenchymal stem cell-derived exosomes.Stem cell research & therapy · 2025Review
- Tremella polysaccharide microneedles loaded with magnetic dental pulp stem cell intracellular vesicles used for androgenic alopecia.Stem cell research & therapy · 2025Article
- Extracellular vesicles: a new frontier in diagnosing and treating graft-versus-host disease after allogeneic hematopoietic cell transplantation.Journal of nanobiotechnology · 2025Review
- Macrophages in graft-versus-host disease (GVHD): dual roles as therapeutic tools and targets.Clinical and experimental medicine · 2025Review
- Identification and validation of tissue-based gene biomarkers for acute intestinal graft-versus-host disease(AIGVHD).Frontiers in immunology · 2025Article
- Sub-inhibitory concentrations of oxacillin modulate biogenesis and function of extracellular vesicles secreted by oxacillin-sensitive methicillin-resistantFrontiers in microbiology · 2025Article
- Effect of pyrroloquinoline quinone on skin aging in Bmi-1 KO mice and underlying mechanisms.PloS one · 2025Article
- Organoids and organoid extracellular vesicles-based disease treatment strategies.Journal of nanobiotechnology · 2024Review
- Extracellular vesicles containing GAS6 protect the liver from ischemia-reperfusion injury by enhancing macrophage efferocytosis via MerTK-ERK-COX2 signaling.Cell death discovery · 2024Article
- Embracing the age of artificial intelligence: paradigm shifts, opportunities, and challenges in the treatment of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.Science China. Life sciences · 2024Article
- Targeting PRMT1 prevents acute and chronic graft-versus-host disease.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Correction: hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype.Journal of hematology & oncology · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
12 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBoth extracellular vesicles from mesenchymal stromal cell-derived human umbilical cords (hUC-EVs) and arsenic trioxides (ATOs) have been demonstrated to treat acute graft-versus-host disease (aGVHD) via immunomodulation. Apart from immunomodulation, hUC-EVs have a unique function of drug delivery, which has been proposed to enhance their efficacy. In this study, we first prepared ATO-loaded hUC-EVs (hUC-EVs-ATO) to investigate the therapeutic effect and potential mechanisms of hUC-EVs-ATO in a mouse model of aGVHD after allogeneic hematopoietic stem cell transplantation (HSCT).
methodsAn aGVHD model was established to observe the therapeutic effects of hUC-EVs-ATO on aGVHD. Target organs were harvested for histopathological analysis on day 14 after transplantation. The effects of hUC-EVs-ATO on alloreactive CD4
resultsThe clinical manifestations and histological scores of aGVHD in the hUC-EVs-ATO group were significantly reduced compared with those in the ATO and hUC-EVs groups. The mice receiving hUC-EVs-ATO lived longer than the control mice. Notably, hUC-EVs-ATO interfering with alloreactive CD4
conclusionshUC-EVs-ATO enhanced the alleviation of aGVHD severity in mice compared with ATO and hUC-EVs without weakening GVL activity. hUC-EVs-ATO promoted M1 to M2 polarization via the mTOR-autophagy pathway. hUC-EVs-ATO could be a potential therapeutic approach in aGVHD after allo-HSCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.